Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Mar 1;4(3):273-286.
doi: 10.1001/jamacardio.2019.0014.

Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial

Affiliations
Randomized Controlled Trial

Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial

Judith S Hochman et al. JAMA Cardiol. .

Erratum in

Abstract

Importance: It is unknown whether coronary revascularization, when added to optimal medical therapy, improves prognosis in patients with stable ischemic heart disease (SIHD) at increased risk of cardiovascular events owing to moderate or severe ischemia.

Objective: To describe baseline characteristics of participants enrolled and randomized in the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial and to evaluate whether qualification by stress imaging or nonimaging exercise tolerance test (ETT) influenced risk profiles.

Design, setting, and participants: The ISCHEMIA trial recruited patients with SIHD with moderate or severe ischemia on stress testing. Blinded coronary computed tomography angiography was performed in most participants and reviewed by a core laboratory to exclude left main stenosis of at least 50% or no obstructive coronary artery disease (CAD) (<50% for imaging stress test and <70% for ETT). The study included 341 enrolling sites (320 randomizing) in 38 countries and patients with SIHD and moderate or severe ischemia on stress testing. Data presented were extracted on December 17, 2018.

Main outcomes and measures: Enrolled, excluded, and randomized participants' baseline characteristics. No clinical outcomes are reported.

Results: A total of 8518 patients were enrolled, and 5179 were randomized. Common reasons for exclusion were core laboratory determination of insufficient ischemia, unprotected left main stenosis of at least 50%, or no stenosis that met study obstructive CAD criteria on study coronary computed tomography angiography. Randomized participants had a median age of 64 years, with 1168 women (22.6%), 1726 nonwhite participants (33.7%), 748 Hispanic participants (15.5%), 2122 with diabetes (41.0%), and 4643 with a history of angina (89.7%). Among the 3909 participants randomized after stress imaging, core laboratory assessment of ischemia severity (in 3901 participants) was severe in 1748 (44.8%), moderate in 1600 (41.0%), mild in 317 (8.1%) and none or uninterpretable in 236 (6.0%), Among the 1270 participants who were randomized after nonimaging ETT, core laboratory determination of ischemia severity (in 1266 participants) was severe (an eligibility criterion) in 1051 (83.0%), moderate in 101 (8.0%), mild in 34 (2.7%) and none or uninterpretable in 80 (6.3%). Among the 3912 of 5179 randomized participants who underwent coronary computed tomography angiography, 79.0% had multivessel CAD (n = 2679 of 3390) and 86.8% had left anterior descending (LAD) stenosis (n = 3190 of 3677) (proximal in 46.8% [n = 1749 of 3739]). Participants undergoing ETT had greater frequency of 3-vessel CAD, LAD, and proximal LAD stenosis than participants undergoing stress imaging.

Conclusions and relevance: The ISCHEMIA trial randomized an SIHD population with moderate or severe ischemia on stress testing, of whom most had multivessel CAD.

Trial registration: ClinicalTrials.gov Identifier: NCT01471522.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Hochman is Principal Investigator for the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial for which, in addition to support by a National Heart, Lung, and Blood Institute grant, devices and medications were provided by Abbott Vascular, Medtronic, Inc, St Jude Medical Inc, Volcano Corporation, Arbor Pharmaceuticals LLC, AstraZeneca, Merck Sharp and Dohme Corp, Omron Healthcare Inc, and financial donations from Arbor Pharmaceuticals LLC and AstraZeneca. Dr Reynolds reports a National Institutes of Health (NIH) ISCHEMIA grant and CIAO-ISCHEMIA ancillary study grant and other support from Abbott Vascular (donation of optical coherence tomography catheters for an unrelated research study). Dr Bangalore receives research grants from the National Heart, Lung, and Blood Institute (for ISCHEMIA and ISCHEMIA-CKD) and Abbott Vascular and is a consultant or receives honoraria from Abbott Vascular, Biotronik, Pfizer, Amgen, Merck, AstraZeneca, and Menarini. Dr Alexander receives grants from Sanofi Aventis, NIH, and Gilead. Dr Goodman reports research grant, salary support, and speaker/consulting honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo, Eli Lilly, Fenix Group International, Ferring Pharmaceuticals, Glaxo Smith Kline, Janssen/Johnson and Johnson, Luitpold Pharmaceuticals, Matrizyme, Merck, Novartis, Pfizer, Regeneron, Sanofi, Servier, Tenax Therapeutics, Heart and Stroke Foundation of Ontario/University of Toronto, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Duke Clinical Research Institute, PERFUSE, and the NIH. Dr Lopes received funding from Bayer; Boehringer Ingleheim, Bristol Myers Squibb, Daiichi Sankyo, Glaxo Smith Kline, Medtronic, Merck, Pfizer, Portola, and Sanofi. Dr White reports grants from the NIH, grants and personal fees from Eli Lilly and Company, Omthera Pharmaceuticals, Pfizer New Zealand, Elsai Inc, DalCor Pharma UK Inc, CSL Behring LLC, Luitpold Pharmaceuticals Ltd, and Sanofi Aventis; personal fees from Sirtex and Acetelion; and personal fees and nonfinancial support from AstraZeneca outside the submitted work. Dr Min receives funding from the Dalio Foundation, NIH, and GE Healthcare; serves on the scientific advisory board of Arineta and GE Healthcare; and has an equity interest in Cleerly. Dr Berman receives software royalties from Cedars-Sinai Medical Center. Dr Spertus reports copyright to Seattle Angina Questionnaire. No other disclosures were reported.

Figures

Figure.
Figure.. Participant Flow From Enrollment to Randomization
Those who were excluded after consent and enrollment are indicated in the right side box. An enrolled participant may have more than 1 reason for being excluded before randomization and therefore may be counted in more than 1 screen failure category (n = 594). Coronary computed tomography angiography (CCTA) was not required in all participants, eg, those with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 or catheterization or CCTA within the prior year. To maximize information about baseline coronary anatomy, we subsequently collected available CCTA images that were performed less than 1 year prior to enrollment for CCTA core laboratory review (n = 148). No obstructive disease was defined as no epicardial coronary artery stenosis at least 50% on study CCTA for participants who were enrolled after stress imaging or no stenosis at least 70% in specified segments for participants who were enrolled after exercise tolerance test. Unprotected left main disease was defined as at least 50% stenosis on study CCTA. Incidental findings were defined as incidental findings on study CCTA of sufficient clinical importance that site investigators did not find randomization appropriate.

Comment in

References

    1. Boden WE, O’Rourke RA, Teo KK, et al. ; COURAGE Trial Research Group . Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-1516. doi:10.1056/NEJMoa070829 - DOI - PubMed
    1. Frye RL, August P, Brooks MM, et al. ; BARI 2D Study Group . A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-2515. doi:10.1056/NEJMoa0805796 - DOI - PMC - PubMed
    1. De Bruyne B, Pijls NH, Kalesan B, et al. ; FAME 2 Trial Investigators . Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991-1001. doi:10.1056/NEJMoa1205361 - DOI - PubMed
    1. Maron DJ, Hochman JS, O’Brien SM, et al. ; ISCHEMIA Trial Research Group . International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: rationale and design. Am Heart J. 2018;201:124-135. doi:10.1016/j.ahj.2018.04.011 - DOI - PMC - PubMed
    1. Shaw LJ, Berman DS, Picard MH, et al. ; National Institutes of Health/National Heart, Lung, and Blood Institute-Sponsored ISCHEMIA Trial Investigators . Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging. 2014;7(6):593-604. doi:10.1016/j.jcmg.2013.10.021 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data